Neuberger Berman Group
TEVA icon

Neuberger Berman Group’s Teva Pharmaceuticals TEVA Stock Holding History

Neuberger Berman Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Sell
40,626
-1,001
-2% -$32.2K ﹤0.01% 1336
2025
Q4 		$1.3M Buy
41,627
+1,780
+4% +$43.9K ﹤0.01% 1320
2025
Q3 		$805K Buy
39,847
+333
+0.8% +$5.85K ﹤0.01% 1434
2025
Q2 		$662K Buy
39,514
+12,158
+44% +$196K ﹤0.01% 1495
2025
Q1 		$420K Sell
27,356
-2,042
-7% -$36.5K ﹤0.01% 1575
2024
Q4 		$648K Sell
29,398
-3,884,672
-99% -$70.7M ﹤0.01% 1449
2024
Q3 		$70.5M Buy
3,914,070
+24,081
+0.6% +$421K 0.06% 372
2024
Q2 		$63.2M Sell
3,889,989
-139,727
-3% -$2.15M 0.05% 372
2024
Q1 		$56.9M Buy
4,029,716
+4,004,205
+15,696% +$50.5M 0.05% 407
2023
Q4 		$266K Buy
25,511
+9,534
+60% +$89K ﹤0.01% 1686
2023
Q3 		$163K Buy
+15,977
New +$149K ﹤0.01% 1715
2020
Q3 		– Sell
-1,718,494
Closed -$21.2M – 1668
2020
Q2 		$21.2M Buy
1,718,494
+140,933
+9% +$1.59M 0.03% 555
2020
Q1 		$14.2M Buy
+1,577,561
New +$16.2M 0.02% 577
2019
Q3 		– Sell
-37,238
Closed -$344K – 1595
2019
Q2 		$344K Sell
37,238
-581,014
-94% -$7.01M ﹤0.01% 1365
2019
Q1 		$9.69M Buy
618,252
+24,591
+4% +$434K 0.01% 748
2018
Q4 		$9.15M Sell
593,661
-4,186
-0.7% -$85.8K 0.01% 746
2018
Q3 		$12.9M Sell
597,847
-9
-0% -$209 0.01% 747
2018
Q2 		$14.5M Buy
597,856
+2,027
+0.3% +$41.3K 0.02% 729
2018
Q1 		$10.2M Buy
595,829
+1,092
+0.2% +$21.3K 0.01% 776
2017
Q4 		$11.3M Sell
594,737
-93,804
-14% -$1.41M 0.01% 756
2017
Q3 		$12.1M Sell
688,541
-176,208
-20% -$3.96M 0.02% 718
2017
Q2 		$28.7M Buy
864,749
+60,853
+8% +$1.88M 0.04% 519
2017
Q1 		$25.8M Sell
803,896
-1,750,432
-69% -$59.7M 0.03% 537
2016
Q4 		$92.6M Sell
2,554,328
-1,829,529
-42% -$73M 0.12% 249
2016
Q3 		$202M Sell
4,383,857
-1,664,770
-28% -$86.9M 0.27% 96
2016
Q2 		$304M Buy
6,048,627
+817,492
+16% +$43.5M 0.42% 47
2016
Q1 		$280M Buy
5,231,135
+1,805,157
+53% +$106M 0.38% 62
2015
Q4 		$225M Sell
3,425,978
-197,588
-5% -$12.2M 0.29% 93
2015
Q3 		$205M Sell
3,623,566
-2,472,633
-41% -$160M 0.26% 110
2015
Q2 		$360M Sell
6,096,199
-509,959
-8% -$31.5M 0.4% 48
2015
Q1 		$412M Buy
6,606,158
+483,048
+8% +$28.1M 0.44% 43
2014
Q4 		$352M Buy
6,123,110
+3,503,300
+134% +$195M 0.37% 60
2014
Q3 		$141M Sell
2,619,810
-76,852
-3% -$4.07M 0.14% 200
2014
Q2 		$141M Buy
2,696,662
+840,745
+45% +$43M 0.14% 211
2014
Q1 		$98.1M Buy
1,855,917
+1,410,625
+317% +$65.2M 0.1% 300
2013
Q4 		$17.8M Buy
445,292
+75,151
+20% +$2.96M 0.02% 673
2013
Q3 		$14M Buy
370,141
+549
+0.1% +$21.4K 0.02% 716
2013
Q2 		$14.5M Buy
+369,592
New +$14.4M 0.02% 679

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group's TEVA Position: Q1 2026 in Review

Neuberger Berman Group reduced its Teva Pharmaceuticals (TEVA) stake by 2.4% in Q1 2026, selling an estimated $32.2K and leaving 40,626 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

Neuberger Berman Group first reported a position in TEVA in Q2 2013 and has held it in 38 quarters since. The position peaked at $412M in Q1 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Neuberger Berman Group held 40,626 shares of Teva Pharmaceuticals worth $1.22M as of Q1 2026.
  • Neuberger Berman Group sold 1,001 Teva Pharmaceuticals shares in Q1 2026, an estimated $32.2K.
  • Teva Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1336 holding.
  • Neuberger Berman Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
  • Neuberger Berman Group's Teva Pharmaceuticals position peaked at $412M in Q1 2015.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.